Effects of Psilocybin

Psilocybin is consumed in various dose ranges which yield different effects on the body and mind.

In this section, we’ll explore the expected effects of a client with a specific dose range. Later in the course, we’ll look at the recommended dose amount and the method of administration to trigger the desired effects.

Subjective Effects

The following effects are experienced under the effect of the medicine:

  • Visual hallucinations

  • Mental imagery with dreamlike qualities

  • Regulate mood

  • Affect primary process thinking

  • Cause changes in personal relevance attribution

  • Reduce activity in cortical areas related to self and social processing

  • Altered perception of time

  • Increased creative thinking process

  • Loosening of organization in brain activity

  • Mystical-type experiences

  • Ego dissolution

  • Visionary restructuralization

  • Oceanic boundlessness (Lowe et al., 2021; Rucker et al., 2022; Kometer et al., 2013; Kometer et al., 2012; Baumeister et al., 2014; Carhart-Harris, Erritzoe, et al., 2012)

Note

The effects mentioned here are for pure synthetic psilocybin, not the expected effects of psilocybin-producing mushrooms. As we will learn when discussing the mechanisms of action, psilocybin-producing mushrooms have other psychoactive compounds and may produce different effects than what is expected simply with psilocybin only (MAPS, 2021).

Long-Term Effects

Psilocybin can have long last effects such as:

  • Decrease in substance cravings

  • Increase in self-efficacy in relation to certain substance use disorders (such as tobacco and alcohol

  • Changes in relationships to past memories (Lowe et al., 2021; Bogenschutz et al., 2015; Johnson et al., 2014)

Learn More

To learn more about the subjective effects of psilocybin, please see tables 3, 4, and 5 in Lowe et al., 2021.

Mystical-Type Experiences

Of the effects associated with the altered state of consciousness seen with psilocybin, mystical-type experiences are one that have been especially focused on in research and user reports since their first documentation by Western science during the now famous "Good Friday" Experiment (Pahnke, 1963). These experiences are sometimes said to be among the most personally meaningful experiences of a person's life, as well as deeply spiritually significant (Griffiths et al., 2008; Griffiths et al., 2006). Mystical-type experiences are said to include:

  • a sense of oneness or unity

  • a sense of sacredness

  • a transcendence of space and time

  • deeply felt positive mood

  • a sense of deep truth or ultimate meaning (i.e., a “noetic” quality of experience)

They are also often difficult to describe, usually going beyond the limited scope of what we are able to communicate with language, often referred to as “ineffability” (Fatur, 2021; Pahnke, 1969). These experiences have been shown to increase prosocial behaviours and attitudes, while creating sustained positive changes to the mood of the user (Griffiths et al., 2008; Griffiths et al., 2006; McCulloch et al., 2022). Some positive effects associated with mystical-type experiences brought about by psilocybin have been shown to last for at least a year after the experience itself, such as a lasting increase in the personality trait Openness which has largely been considered durable and relatively fixed (MacLean et al., 2011).

Justice, Equity, Dignity, and Inclusion Callout

However, mystical-type experiences are not exclusively caused by psilocybin. They are caused by other substances as well as non-substance–related practices such as meditation. Cultural perceptions of (and reactions to) such mystical-type experiences may potentially vary.

The Arc of Psilocybin-Assisted Therapy

In the timeline below, we can see at what point during a Medicine Session the clients experience the effects.

Please ensure that you read through all events before proceeding by using the arrows to navigate through the timeline. If using a screen reader, the whole text will be read automatically.

In the following image, you can see how clients experience the peak effect of psilocybin and at what point during the session depending on a high or low dose and the degree to which they were emotionally supported through the session.

Adapted from Griffiths et al., 2018 licensed under CC BY-NC 4.0

Health Professional Tip

How does microdosing fit into Psilocybin-Assisted Therapy?

Psilocybin is among the most frequently used substances when it comes to microdosing with different effects said to emerge as a result of the smaller doses being used (Fatur, 2021; Ona & Bouso, 2020). Microdosing is the regular consumption of psilocybin at very low doses usually around one tenth or one twentieth of a typical dose. Users do not typically experience any hallucinations (Rush et al., 2022).

Although users report many benefits to microdosing psilocybin, such as increases in mental wellness and creativity, enhanced attention and cognitive abilities, and many others, clinical trials on the topic are lacking and existing research on psilocybin microdosing is marred by a number of control- and variable-related issues (Fatur, 2021; Ona & Bouso, 2020). Many research publications on the topic of psilocybin microdosing conflate the effects of higher doses of psilocybin as well as psilocybin when used in psychedelic-assisted therapy with those that can be expected from microdosing, providing a misleading picture of the practice.

A microdose is not typically administered during psilocybin-assisted therapy. As a result, Microdosing is not a main focus of Numinus’ certification pathway.

References

Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. (2014). Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol, 4(4), 156- 169. https://doi.org/10.1177/2045125314527985

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299. https://doi.org/10.1177/0269881114565144

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., . . . Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A, 109(6), 2138-2143. https://doi.org/10.1073/pnas.1119598109

Fatur, K. (2021). Peculiar plants and fantastic fungi: An ethnobotanical study of the use of hallucinogenic plants and mushrooms in Slovenia. PLoS One, 16(1), e0245022. https://doi.org/10.1371/journal.pone.0245022

Griffiths, R. R., Johnson, M. W., Richards, W. A., … Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32(1), 49-69. doi:10.1177/0269881117731279

Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol, 22(6), 621-632. https://doi.org/10.1177/0269881108094300

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5- HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol, 28(11), 983- 992. https://doi.org/10.1177/0269881114548296

Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry, 72(11), 898-906. https://doi.org/10.1016/j.biopsych.2012.04.005

Kometer, M., Schmidt, A., Jäncke, L., & Vollenweider, F. X. (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci, 33(25), 10544-10551. https://doi.org/10.1523/JNEUROSCI.3007-12.2013

Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules (Basel, Switzerland), 26(10), 2948. https://doi.org/10.3390/molecules26102948

MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol, 25(11), 1453-1461. https://doi.org/10.1177/0269881111420188

MAPS. (2021). MDMA Investigator Brochure.

McCulloch, D. E., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., . . . Stenbæk, D. S. (2022). Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Front Pharmacol, 13, 841648. https://doi.org/10.3389/fphar.2022.841648

Ona, G., & Bouso, J. C. (2020). Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review. Neurosci Biobehav Rev, 119, 194-203. https://doi.org/10.1016/j.neubiorev.2020.09.035

Pahnke, W. M. (1963). Drugs & Mysticism: An Analysis of the Relationship between Psychedelic Drugs and Mystical Consciousness. Harvard University.

Rucker, J. J., Marwood, L., Ajantaival, R.-L. J., & Young, A. H. (2022). The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Journal of Psychopharmacology. 36, 1. 114-125. doi:10.1177/02698811211064720

Rush, B., Marcus, O., Shore, R., Cunningham, L., Thomson, N., and Rideout, K. (2022). Psychedelic Medicine: A Rapid Review of Therapeutic Applications and Implications for Future Research. Homewood Research Institute. https://hriresearch.com/research/exploratory- research/research-reports/